PLIANT THERAPEUTICS, INC. - 8-K Filing
Pliant Therapeutics reported Q1 2026 financial results with a net loss of $20.0 million compared to $56.2 million in the prior-year quarter due to reduced R&D expenses ($13.6M vs. $43.4M) and G&A costs ($8.2M vs. $15.5M). The company announced initiation of its Phase 1b trial FORTIFY for PLN-101095 in ICI-refractory solid tumors, with first patient dosed in April 2026. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $PLRX